Patent application number | Description | Published |
20090005397 | Substituted Oxindol Derivatives and Medicaments Containing the Same - The invention relates to novel oxindol derivatives of general formula (1) wherein the substituents A, B, R | 01-01-2009 |
20100041698 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS BINDING PARTNERS FOR 5-HT5 RECEPTORS - The invention relates to compounds of general formula (I), corresponding enantiomeric, diastereomeric and/or tautomeric forms thereof as well as pharmaceutically acceptable salts thereof and the prodrugs of said compounds. The invention also relates to the use of said compounds as binding partners for 5-HT5 receptors for treating diseases that are modulated by a 5-HT5 receptor activity, in particular, for treating neurodegenerative and neuropsychiatric disorders as well as signs, symptoms and dysfunctions. | 02-18-2010 |
20100184787 | Heataryl-substituted guanidine compounds and use thereof as binding partners for 5-ht5-receptors - The invention relates to the hetaryl-substituted guanidine compounds of general formula (I), enantiomeres, diastereomeres and/or tautomeres thereof, in addition to the pharmaceutically acceptable salts thereof and the prodrugs of the known compounds. The invention also relates to the use of said hetaryl-substituted guanidine compounds as binding partners for 5-HT5-receptors for treating and/or for the prophylaxis of illnesses which are modulated by a 5-HT5-receptor activity, in particular, for treating and/or for the prophylaxis of neurodegenerative and neuropsychiatric disorders, and signs, symptoms and dysfunctions associated with said disorders. | 07-22-2010 |
20100273766 | SUBSTITUTED OXINDOL DERIVATIVES, MEDICAMENTS CONTAINING SAID DERIVATIVES AND USE THEREOF - The invention relates to novel oxindole derivatives of general formula (I), wherein the substituents R | 10-28-2010 |
20110071132 | SUBSTITUTED OXINDOLE DERIVATIVES, DRUGS CONTAINING SAID DERIVATIVES AND THE USE THEREOF - The invention relates to novel oxindol derivative of general formula (I), wherein substituents R | 03-24-2011 |
20110071156 | HETEROARYL-SUBSTITUTED 1,3-DIHYDROINDOL-2-ONE DERIVATIVES AND MEDICAMENTS CONTAINING THEM - The present invention relates to novel 1,3-dihydroindol-2-one (oxindole) derivatives of the formula (I) in which A, R | 03-24-2011 |
20110077241 | HETEROARYL-SUBSTITUTED 1,3-DIHYDROINDOL-2-ONE DERIVATIVES AND MEDICAMENTS CONTAINING THEM - The present invention relates to novel 1,3-dihydroindol-2-one (oxindole) derivatives of the formula (I) in which A, R | 03-31-2011 |
20110151023 | COMBINATION THERAPY WITH PARP INHIBITORS - The present invention describes benzimidazole derivatives of Formula (I) which constitute potent PARP inhibitors in combination with radiotherapy or in combination with other chemotherapeutic agents. | 06-23-2011 |
20110152336 | COMBINATION THERAPY WITH PARP INHIBITORS - The present invention describes benzimidazole derivatives of Formula (I) which constitute potent PARP inhibitors in combination with radiotherapy or in combination with other chemotherapeutic agents. | 06-23-2011 |
20110178294 | NOVEL CARBOXYLIC ACID DERIVATIVES, THEIR PREPARATION AND USE - Carboxylic acid derivatives | 07-21-2011 |
20110207788 | 5-Ring Heteroaromatic compounds and their use as binding partners for 5-ht5 receptors - The invention relates to 5-ring heteroaromatic compounds of general formula (I), their use for the treatment and/or prevention of diseases, and medicaments containing same. | 08-25-2011 |
20110237589 | GUANIDINE COMPOUNDS, AND USE THEREOF AS BINDING PARTNERS FOR 5-HT5 RECEPTORS - The present invention relates to guanidine compounds of the general formula I | 09-29-2011 |
20110257194 | SUBSTITUTED OXINDOL DERIVATIVES AND MEDICAMENTS CONTAINING THE SAME - The present invention relates to novel oxindole derivatives of the general formula (I), | 10-20-2011 |
20120045524 | COMBINATION THERAPY WITH PARP INHIBITORS - The present invention describes benzimidazole derivatives of Formula (I) which constitute potent PARP inhibitors in combination with radiotherapy or in combination with other chemotherapeutic agents. | 02-23-2012 |
20120088911 | NOVEL CARBOXYLIC ACID DERIVATIVES, THEIR PREPARATION AND USE | 04-12-2012 |
20120136001 | SUBSTITUTED OXINDOLE DERIVATIVES, MEDICAMENTS CONTAINING THE LATTER AND USE THEREOF - The invention relates to novel oxindole derivatives of general formula (I), in which the substituents A, B, R | 05-31-2012 |
20130005703 | QUINOLINE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE SEROTONIN-5-HT6 RECEPTOR - The present invention relates to novel quinoline compounds of the formula (I) and to the salts thereof. The compounds possess valuable therapeutic properties and are particularly suitable, for treating diseases that respond to modulation of the serotonin 5-HT | 01-03-2013 |
20130029966 | SUBSTITUTED OXINDOLE DERIVATIVES, MEDICAMENTS CONTAINING SAID DERIVATIVES AND USE THEREOF - The invention relates to novel oxindole derivatives of general formula (I), wherein the substituents R | 01-31-2013 |
20130317044 | NOVEL CARBOXYLIC ACID DERIVATIVES, THEIR PREPARATION AND USE - Carboxylic acid derivatives | 11-28-2013 |
20130324537 | GUANIDINE COMPOUNDS, AND USE THEREOF AS BINDING PARTNERS FOR 5-HT5 RECEPTORS - The present invention relates to guanidine compounds of the general formula I | 12-05-2013 |
20140187543 | HETEROARYL-SUBSTITUTED 1,3-DIHYDROINDOL-2-ONE DERIVATIVES AND MEDICAMENTS CONTAINING THEM - The present invention relates to novel 1,3-dihydroindol-2-one (oxindole) derivatives of the formula (I) | 07-03-2014 |
20140221371 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS BINDING PARTNERS FOR 5-HT5 RECEPTORS - The invention relates to compounds of general formula (I), corresponding enantiomeric, diastereomeric and/or tautomeric forms thereof as well as pharmaceutically acceptable salts thereof and the prodrugs of said compounds. The invention also relates to the use of said compounds as binding partners for 5-HT5 receptors for treating diseases that are modulated by a 5-HT5 receptor activity, in particular, for treating neurodegenerative and neuropsychiatric disorders as well as signs, symptoms and dysfunctions. | 08-07-2014 |